Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
This piece breaks down the core influences on market indices, from macro indicators to liquidity, helping you anticipate possible moves.
27,686 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
European leaders weigh price caps on essentials to curb inflation, a move that has CEOs warning of market distortions...
Chip stocks setting records kept up the rally as AI demand supports semiconductors, but a cooling RSI and a hidden be...
As policymakers push a universal 401(K) plan, the trump’s universal 401(k) architect outlines the trust challenges fa...
A policy push to cover GLP-1 drugs for weight loss under Medicare stalled, leaving many beneficiaries in the middle. ...
The latest data show core PCE at a 9-month high, complicating the Fed’s plan for rate cuts as investors recalibrate b...
Markets wobble as U.S. military actions in Iran escalate costs. Analysts warn the real burden may extend well beyond ...
New University of Michigan data show consumer sentiment collapsing to a 75-year low, highlighting a growing consumer-...
SpaceX headlines grab attention, but smart investors look for durable earnings growth in established aerospace player...
The Jets ETF has breached critical chart support, suggesting airline stocks face risks beyond rising fuel costs. Tech...
SEA’s December 2025 payout fell 60% from 2024, exposing how its dividend is tied to cyclical freight profits rather t...
A little-known aerospace stock has delivered a blistering 470% gain over five years and recently reached a fresh all-...